Matt Zeller, country president of Novartis Australia and New Zealand, said, “The impact of CVD in Australia is devastating, claiming one life every 12 minutes. Now, Leqvio is available on the PBS and this first-in-class treatment option has the potential to transform patient care and help improve the lives of individuals living with CVD.”
Novartis welcomes the listing of first-in-class cholesterol-lowering therapy
April 2, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
The need to honour a strong history while ensuring the future is guided by the 'good guys'
November 17, 2025 - - Latest News -
BMS Australia team cycles across Japan, raising nearly $20,000 for Bowel Cancer Australia
November 17, 2025 - - Latest News -
Syntara secures positive European opinion for orphan designation of amsulostat in myelofibrosis
November 17, 2025 - - Australian Biotech -
Mesoblast appoints Chief Financial Officer as it evolves into fully integrated commercial organisation
November 17, 2025 - - Australian Biotech -
Argent BioPharma secures significant financing facility to support strategic expansion
November 17, 2025 - - Australian Biotech -
Race Oncology launches new clinical programs in AML and lung cancer
November 17, 2025 - - Australian Biotech -
Noxopharm begins daily dosing in second phase of HERACLES trial
November 17, 2025 - - Australian Biotech